United Therapeutics (UTHR) News Today $290.75 -0.97 (-0.33%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$286.00 -4.75 (-1.63%) As of 06/20/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock UTHR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Retirement Systems of Alabama Sells 11,423 Shares of United Therapeutics Corporation (NASDAQ:UTHR)Retirement Systems of Alabama reduced its position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 8.8% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 118,188 shares of the biotechnology company'sJune 21 at 4:48 AM | marketbeat.comCWA Asset Management Group LLC Raises Holdings in United Therapeutics Corporation (NASDAQ:UTHR)CWA Asset Management Group LLC grew its holdings in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 51.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,224 shares of the biotechnology company's stock afJune 19 at 5:15 AM | marketbeat.comUnited Therapeutics Corporation (NASDAQ:UTHR) EVP Sells $3,079,560.00 in StockJune 19 at 4:47 AM | americanbankingnews.comGreat Lakes Retirement Inc. Acquires Shares of 4,014 United Therapeutics Co. (NASDAQ:UTHR)Great Lakes Retirement Inc. bought a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 4,014 shares of the biotechnology company's stock, valuedJune 17, 2025 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) EVP Sells $3,079,560.00 in StockJune 17, 2025 | insidertrades.comPaul A. Mahon Sells 11,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockUnited Therapeutics Co. (NASDAQ:UTHR - Get Free Report) EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $279.96, for a total value of $3,079,560.00. Following the transaction, the executive vice president now directly owns 36,781 shares in the company, valued at approximately $10,297,208.76. This represents a 23.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.June 16, 2025 | marketbeat.com328,783 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Vaughan Nelson Investment Management L.P.Vaughan Nelson Investment Management L.P. bought a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 328,783 shares of the biotechnology company's stocJune 15, 2025 | marketbeat.comSG Americas Securities LLC Grows Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)SG Americas Securities LLC raised its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 210.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,085 shares of the biotechnology compaJune 14, 2025 | marketbeat.comTobam Sells 11,834 Shares of United Therapeutics Co. (NASDAQ:UTHR)Tobam reduced its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 64.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,388 shares of the biotechnology company's stock after selling 11,834 shares durJune 13, 2025 | marketbeat.com3,900 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by Polianta LtdPolianta Ltd purchased a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 3,900 shares of the biotechnology company's stJune 13, 2025 | marketbeat.comGreenwood Capital Associates LLC Acquires Shares of 2,349 United Therapeutics Co. (NASDAQ:UTHR)Greenwood Capital Associates LLC bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 2,349 shares ofJune 13, 2025 | marketbeat.comAssenagon Asset Management S.A. Purchases 10,290 Shares of United Therapeutics Co. (NASDAQ:UTHR)Assenagon Asset Management S.A. grew its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 18.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 65,405 shares of the biotechnologyJune 13, 2025 | marketbeat.comBank of America Lowers United Therapeutics (NASDAQ:UTHR) Price Target to $315.00June 13, 2025 | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Price Target Cut to $315.00 by Analysts at Bank of AmericaBank of America lowered their price objective on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a report on Wednesday.June 11, 2025 | marketbeat.comUnited Therapeutics: Tanking On Rival's PAH Data - I'd Consider Buying StockJune 11, 2025 | seekingalpha.comJames Edgemond Sells 12,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockUnited Therapeutics Co. (NASDAQ:UTHR - Get Free Report) CFO James Edgemond sold 12,000 shares of the business's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $325.37, for a total value of $3,904,440.00. Following the sale, the chief financial officer now directly owns 8,118 shares in the company, valued at approximately $2,641,353.66. The trade was a 59.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.June 10, 2025 | marketbeat.comInsmed Stock Soars on Pulmonary Arterial Hypertension Drug Trial ResultsJune 10, 2025 | msn.comUnited Therapeutics (NASDAQ:UTHR) Shares Gap Down - Here's What HappenedUnited Therapeutics (NASDAQ:UTHR) Shares Gap Down - Here's WhyJune 10, 2025 | marketbeat.comAtwood & Palmer Inc. Sells 879 Shares of United Therapeutics Co. (NASDAQ:UTHR)Atwood & Palmer Inc. cut its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 1.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 63,696 shares of the biotechnology company's stock afterJune 10, 2025 | marketbeat.comCantor Fitzgerald Forecasts UTHR FY2026 EarningsUnited Therapeutics Co. (NASDAQ:UTHR - Free Report) - Cantor Fitzgerald issued their FY2026 EPS estimates for United Therapeutics in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer anticipates that the biotechnology company will post earnings per share of $29.2June 10, 2025 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Holdings Raised by Nepsis Inc.Nepsis Inc. grew its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 6.7% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 58,574 shares of the biotechnology company's stock after buying an additional 3,653 shares during the quarter. United TherapJune 10, 2025 | marketbeat.comLiquidia, United Therapeutics fall after mid-stage data for Insmed’s PAH assetJune 10, 2025 | seekingalpha.comUnited Therapeutics Co. (NASDAQ:UTHR) Stock Position Lowered by Livforsakringsbolaget Skandia OmsesidigtLivforsakringsbolaget Skandia Omsesidigt lessened its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 25.3% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 21,000 shares of the biotechnology company's stock afJune 10, 2025 | marketbeat.comToth Financial Advisory Corp Has $404,000 Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)Toth Financial Advisory Corp trimmed its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 57.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,310 shares of the biotechnology company's stock aftJune 10, 2025 | marketbeat.comQ2 EPS Forecast for United Therapeutics Boosted by AnalystUnited Therapeutics Co. (NASDAQ:UTHR - Free Report) - Equities research analysts at Leerink Partnrs raised their Q2 2025 earnings per share estimates for United Therapeutics in a report released on Wednesday, June 4th. Leerink Partnrs analyst R. Ruiz now anticipates that the biotechnology companyJune 9, 2025 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Wedge Capital Management L L P NCWedge Capital Management L L P NC boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 35.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 107,276 shares of the biotechnology comJune 8, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Purchases 1,970 Shares of United Therapeutics Co. (NASDAQ:UTHR)Hennion & Walsh Asset Management Inc. grew its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 84.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,297 shJune 7, 2025 | marketbeat.comUnited Therapeutics: A Cheap But Complicated TaleJune 6, 2025 | seekingalpha.comLeerink Partnrs Brokers Increase Earnings Estimates for UTHRUnited Therapeutics Co. (NASDAQ:UTHR - Free Report) - Equities researchers at Leerink Partnrs upped their Q3 2025 earnings estimates for shares of United Therapeutics in a research note issued on Wednesday, June 4th. Leerink Partnrs analyst R. Ruiz now expects that the biotechnology company willJune 6, 2025 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Rhumbline AdvisersRhumbline Advisers trimmed its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 1.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 124,900 shares of the biotechnology company's stock after selJune 5, 2025 | marketbeat.comCorcept (CORT) Down 1.7% Since Last Earnings Report: Can It Rebound?June 4, 2025 | finance.yahoo.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Veracity Capital LLCVeracity Capital LLC reduced its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 43.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,422 shares of the biotechnologyJune 4, 2025 | marketbeat.comUnigestion Holding SA Makes New $2.67 Million Investment in United Therapeutics Co. (NASDAQ:UTHR)Unigestion Holding SA bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 8,668 shares of the biotechnology company's stJune 3, 2025 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Milestone Asset Management LLCMilestone Asset Management LLC lowered its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 76.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 684 shares of thJune 3, 2025 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by GAMMA Investing LLCGAMMA Investing LLC raised its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 29,415.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 221,954 shares of the biotechnology company's stock afteJune 3, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage of United Therapeutics (UTHR) with Overweight RecommendationJune 2, 2025 | msn.comUnited Therapeutics (NASDAQ:UTHR) Coverage Initiated at Cantor FitzgeraldCantor Fitzgerald started coverage on shares of United Therapeutics in a research note on Monday. They issued an "overweight" rating and a $405.00 target price for the company.June 2, 2025 | marketbeat.comUnited Therapeutics (UTHR) Receives Overweight Rating from Cantor Fitzgerald | UTHR Stock NewsJune 2, 2025 | gurufocus.comUnited Therapeutics Co. (NASDAQ:UTHR) EVP Paul A. Mahon Sells 11,000 SharesUnited Therapeutics Co. (NASDAQ:UTHR - Get Free Report) EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction on Thursday, May 29th. The shares were sold at an average price of $316.07, for a total value of $3,476,770.00. Following the completion of the transaction, the executive vice president now owns 36,781 shares in the company, valued at $11,625,370.67. The trade was a 23.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.May 31, 2025 | marketbeat.comSummit Global Investments Has $4.33 Million Position in United Therapeutics Co. (NASDAQ:UTHR)Summit Global Investments reduced its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 61.0% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 14,058 shares of the biotechnology company's stock after selling 22,023 shaMay 31, 2025 | marketbeat.comCalifornia State Teachers Retirement System Sells 6,861 Shares of United Therapeutics Co. (NASDAQ:UTHR)California State Teachers Retirement System lowered its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 9.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 62,979 shares of the biotechnology compMay 31, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Takes $16.51 Million Position in United Therapeutics Co. (NASDAQ:UTHR)Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acMay 31, 2025 | marketbeat.com13,541 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by Lansforsakringar Fondforvaltning AB publLansforsakringar Fondforvaltning AB publ acquired a new position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 13,541 shares ofMay 30, 2025 | marketbeat.comPublic Employees Retirement System of Ohio Sells 1,090 Shares of United Therapeutics Co. (NASDAQ:UTHR)Public Employees Retirement System of Ohio trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 6.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,291 shares of the biotechnoloMay 30, 2025 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) have been given an average rating of "Moderate Buy" by the twelve analysts that are presently covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating toMay 30, 2025 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Voloridge Investment Management LLCVoloridge Investment Management LLC increased its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 47.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,864 shares of tMay 29, 2025 | marketbeat.comPolar Asset Management Partners Inc. Takes $7.80 Million Position in United Therapeutics Co. (NASDAQ:UTHR)Polar Asset Management Partners Inc. purchased a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 22,100 shares of tMay 28, 2025 | marketbeat.comLiquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal ChallengeMay 27, 2025 | benzinga.comGF Fund Management CO. LTD. Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR)GF Fund Management CO. LTD. bought a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 937 shares of the biotechnology company's stock, valued at approximately $331,000.May 27, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Position in United Therapeutics Co. (NASDAQ:UTHR)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 9.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 232May 27, 2025 | marketbeat.com Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Email Address UTHR Media Mentions By Week UTHR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. UTHR News Sentiment▼1.250.65▲Average Medical News Sentiment UTHR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. UTHR Articles This Week▼814▲UTHR Articles Average Week Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ALNY News BIIB News INCY News NBIX News EXEL News BMRN News EXAS News RGEN News HALO News MDGL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:UTHR) was last updated on 6/22/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe Biggest Story of My Decade-Long Career in Silicon ValleySteve Jobs' Lost 'Product' Could Save Tesla On July 21st, a revolutionary announcement could transform Tesl...InvestorPlace | Sponsored379 passengers walked away from thisForget OpenAI, ChatGPT, and the $2 trillion chip race… The real story is buried inside a new U.S. patent. E...True Market Insiders | SponsoredA grave, grave error.It seems like the world is on fire. Trump’s tariffs are crippling economies worldwide. Canada’s been cri...Porter & Company | SponsoredTrump Makes Major Crypto AnnouncementTrump's crypto revolution is now fully underway and now, we believe he’s about to deliver on his biggest promi...Crypto 101 Media | SponsoredWar Tensions Are Making Gold Rise to Record HighsIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy UTHR Stock Free UTHR Stock Alerts